Clinical Trial Update: RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RC48 plus toripalimab and radiotherapy for bladder-sparing treatment in muscle invasive bladder cancer with HER2 expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• RC48 (disitamab vedotin)
• Radiotherapy
• Toripalimab (Toripalimab)

Snippet

Sponsor: RenJi Hospital | Conditions: Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Status: UNKNOWN